Next Century Growth Investors LLC Sells 22,800 Shares of Boston Scientific Co. (NYSE:BSX)

Next Century Growth Investors LLC reduced its holdings in Boston Scientific Co. (NYSE:BSX) by 52.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,422 shares of the medical equipment provider’s stock after selling 22,800 shares during the period. Next Century Growth Investors LLC’s holdings in Boston Scientific were worth $1,824,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Sunbelt Securities Inc. raised its position in shares of Boston Scientific by 16.6% in the 3rd quarter. Sunbelt Securities Inc. now owns 1,414 shares of the medical equipment provider’s stock valued at $118,000 after acquiring an additional 201 shares during the period. Soltis Investment Advisors LLC acquired a new stake in Boston Scientific in the third quarter worth $240,000. M&T Bank Corp boosted its position in shares of Boston Scientific by 0.3% during the third quarter. M&T Bank Corp now owns 106,127 shares of the medical equipment provider’s stock worth $8,894,000 after purchasing an additional 370 shares in the last quarter. Passumpsic Savings Bank acquired a new position in shares of Boston Scientific in the 3rd quarter valued at $3,015,000. Finally, World Investment Advisors LLC raised its stake in Boston Scientific by 50.9% during the 3rd quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider’s stock worth $979,000 after buying an additional 3,939 shares during the period. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares in the company, valued at $2,966,329.50. This trade represents a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares in the company, valued at $560,103.60. This trade represents a 75.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 133,183 shares of company stock valued at $13,948,476 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 1.1 %

Shares of NYSE:BSX opened at $93.66 on Friday. The company has a market cap of $138.53 billion, a price-to-earnings ratio of 74.93, a PEG ratio of 2.79 and a beta of 0.73. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17. The firm’s 50-day simple moving average is $100.54 and its 200-day simple moving average is $94.02. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. As a group, equities research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Piper Sandler increased their price target on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a report on Monday, February 3rd. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Raymond James upped their target price on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Finally, JPMorgan Chase & Co. boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $109.04.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.